SN source of ascertainment (percentage) among patients with at least 1 reported SN within the linked CIBMTR–CCR data set of 18 450 patients. Includes patients diagnosed with a solid SN in the breast, brain and CNS, lung, GI and GU tracts, oropharynx, or thyroid, or sarcoma or melanoma after the first HCT and before the end of follow-up (defined as the earliest occurrence of a second HCT, death, last known alive status from either CCR or CIBMTR, or the study end date [31 December 2018]). For this figure, patients with multiple SN types were counted once.